Over the last 5 years, the share price of TCC Concept has gained 93.49% CAGR. Over the past year, the corresponding return has been -6.98%. TCC Concept’s current P/E of 41.04x helps give context to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the ...